Needham & Company Sees 150% Upside in Cytokinetics (CYTK) after Expanded Amgen (AMGN) Deal
Needham & Company's Chad Messer boosted his price target on Buy-rated Cytokinetics (NASDAQ: CYTK) from $2.50 to $3.50 Thursday, following expansion of the Amgen (NASDAQ: AMGN) deal for heart failure drug Omecamtiv in Japan.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.